Overview Dividends

(TMHC) Taylor Morn Home - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US87724P1066

Single-Family, Multi-Family, Master-Planned, Commercial, Build-To-Rent

TMHC EPS (Earnings per Share)

EPS Growth (3Y CAGR): -8.33%
EPS Trend (3Y Correlation): 16.7%

TMHC Revenue

Revenue Growth (3Y CAGR): -6.10%
Revenue Trend (3Y Correlation): 13.1%

Risk
Volatility	33.6%
Value at Risk 5%th	52.4%

Reward
Sharpe Ratio	-0.47
Alpha	-43.36

Character
Hurst Exponent	0.386
Beta	1.614

Drawdowns 3y
Max DD	27.90%
Mean DD	9.07%

Description: TMHC Taylor Morn Home November 06, 2025

Taylor Morrison Home Corp. (NYSE: TMHC) is a U.S. land developer and homebuilder that designs, builds, and sells single- and multi-family detached and attached homes, plus lifestyle and master-planned communities. Its portfolio also includes multi-use projects (commercial, retail, and multifamily) under the Urban Form brand, financial and settlement services, and a build-to-rent operation (Yardly). The company markets homes under the Taylor Morrison, Darling Homes Collection, and Esplanade brands across 13 states, from Arizona to Washington.

Key operational metrics (FY 2023): revenue of $5.9 billion, 13,300 homes delivered, and an average selling price (ASP) of $447 k-about 4% above the industry median. Inventory stood at ≈ 3,200 units, giving a sell-through rate of roughly 70% in a market where mortgage rates have hovered near 7%, a primary driver of demand elasticity for homebuilders.

Given TMHC’s exposure to regional price differentials and its diversification into rent-to-own (Yardly) and mixed-use assets, a deeper quantitative view-such as inventory turnover, price-to-sales ratios, and sensitivity to interest-rate shifts-can be explored on the ValueRay platform.

TMHC Stock Overview

Market Cap in USD	5,715m
Sub-Industry	Homebuilding
IPO / Inception	2013-04-10

TMHC Stock Ratings

Growth Rating	52.3%
Fundamental	66.7%
Dividend Rating	-
Return 12m vs S&P 500	-28.3%
Analyst Rating	4.30 of 5

TMHC Dividends

Currently no dividends paid

TMHC Growth Ratios

Growth Correlation 3m	-82.2%
Growth Correlation 12m	-9.3%
Growth Correlation 5y	88.3%
CAGR	28.44%
CAGR/Max DD Calmar Ratio	1.02
CAGR/Mean DD Pain Ratio	3.13
Current Volume	1050.2k
Average Volume	1148k

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (853.6m TTM) > 0 and > 6% of Revenue (6% = 502.7m TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA 5.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 77.90% (prev 81.08%; Δ -3.17pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.06 (>3.0%) and CFO 619.3m <= Net Income 853.6m (YES >=105%, WARN >=100%)

Net Debt (1.89b) to EBITDA (1.28b) ratio: 1.48 <= 3.0 (WARN <= 3.5)

Current Ratio 7.09 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (100.0m) change vs 12m ago -5.69% (target <= -2.0% for YES)

Gross Margin 23.96% (prev 24.45%; Δ -0.49pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 88.53% (prev 84.21%; Δ 4.32pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 30.59 (EBITDA TTM 1.28b / Interest Expense TTM 40.9m) >= 6 (WARN >= 3)

Altman Z'' 8.56

(A) 0.68 = (Total Current Assets 7.60b - Total Current Liabilities 1.07b) / Total Assets 9.63b

(B) 0.52 = Retained Earnings (Balance) 5.00b / Total Assets 9.63b

(D) 1.46 = Book Value of Equity 5.00b / Total Liabilities 3.43b

Total Rating: 8.56 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 66.71

1. Piotroski 6.0pt = 1.0

2. FCF Yield 7.62% = 3.81

3. FCF Margin 6.92% = 1.73

4. Debt/Equity 0.37 = 2.43

5. Debt/Ebitda 1.48 = 1.00

6. ROIC - WACC (= 2.98)% = 3.73

7. RoE 14.20% = 1.18

8. Rev. Trend 13.15% = 0.99

9. EPS Trend 16.68% = 0.83

What is the price of TMHC shares?

As of November 10, 2025, the stock is trading at USD 59.31 with a total of 1,050,200 shares traded.
Over the past week, the price has changed by +1.42%, over one month by -4.35%, over three months by -7.50% and over the past year by -18.70%.

Is Taylor Morn Home a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Taylor Morn Home (NYSE:TMHC) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 66.71 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TMHC is around 60.46 USD . This means that TMHC is currently overvalued and has a potential downside of 1.94%.

Is TMHC a buy, sell or hold?

Taylor Morn Home has received a consensus analysts rating of 4.30. Therefore, it is recommended to buy TMHC.

Strong Buy: 4
Buy: 5
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the TMHC price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	73.6	24.1%
Analysts Target Price	73.6	24.1%
ValueRay Target Price	67.5	13.9%

TMHC Fundamental Data Overview November 05, 2025

Market Cap USD = 5.71b (5.71b USD * 1.0 USD.USD)
P/E Trailing = 7.0458
P/E Forward = 10.6045
P/S = 0.6821
P/B = 1.0984
P/EG = 1.511
Beta = 1.614
Revenue TTM = 8.38b USD
EBIT TTM = 1.25b USD
EBITDA TTM = 1.28b USD
Long Term Debt = 2.12b USD (from longTermDebt, last fiscal year)
Short Term Debt = 73.0m USD (from shortTermDebt, last quarter)
Debt = 2.26b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.89b USD (from netDebt column, last quarter)
Enterprise Value = 7.61b USD (5.71b + Debt 2.26b - CCE 370.6m)
Interest Coverage Ratio = 30.59 (Ebit TTM 1.25b / Interest Expense TTM 40.9m)
FCF Yield = 7.62% (FCF TTM 580.0m / Enterprise Value 7.61b)
FCF Margin = 6.92% (FCF TTM 580.0m / Revenue TTM 8.38b)
Net Margin = 10.19% (Net Income TTM 853.6m / Revenue TTM 8.38b)
Gross Margin = 23.96% ((Revenue TTM 8.38b - Cost of Revenue TTM 6.37b) / Revenue TTM)
Gross Margin QoQ = 22.74% (prev 23.56%)
Tobins Q-Ratio = 0.79 (Enterprise Value 7.61b / Total Assets 9.63b)
Interest Expense / Debt = 0.56% (Interest Expense 12.8m / Debt 2.26b)
Taxrate = 24.94% (67.9m / 272.4m)
NOPAT = 939.9m (EBIT 1.25b * (1 - 24.94%))
Current Ratio = 7.09 (Total Current Assets 7.60b / Total Current Liabilities 1.07b)
Debt / Equity = 0.37 (Debt 2.26b / totalStockholderEquity, last quarter 6.18b)
Debt / EBITDA = 1.48 (Net Debt 1.89b / EBITDA 1.28b)
Debt / FCF = 3.26 (Net Debt 1.89b / FCF TTM 580.0m)
Total Stockholder Equity = 6.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.87% (Net Income 853.6m / Total Assets 9.63b)
RoE = 14.20% (Net Income TTM 853.6m / Total Stockholder Equity 6.01b)
RoCE = 15.40% (EBIT 1.25b / Capital Employed (Equity 6.01b + L.T.Debt 2.12b))
RoIC = 11.67% (NOPAT 939.9m / Invested Capital 8.05b)
WACC = 8.69% (E(5.71b)/V(7.98b) * Re(11.96%) + D(2.26b)/V(7.98b) * Rd(0.56%) * (1-Tc(0.25)))
Discount Rate = 11.96% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -4.18%
[DCF Debug] Terminal Value 65.15% ; FCFE base≈356.0m ; Y1≈353.4m ; Y5≈369.4m
Fair Price DCF = 37.91 (DCF Value 3.70b / Shares Outstanding 97.7m; 5y FCF grow -1.47% → 3.0% )
EPS Correlation: 16.68 | EPS CAGR: -8.33% | SUE: 0.96 | # QB: 1
Revenue Correlation: 13.15 | Revenue CAGR: -6.10% | SUE: 0.65 | # QB: 0

Additional Sources for TMHC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle